Lv41
428 积分 2021-01-06 加入
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
2小时前
已完结
Multiple primary lung cancer: Updates and perspectives
12天前
已完结
Multiple primary lung cancer: A literature review
12天前
已完结
Cancer statistics, 2020
15天前
已完结
Overcoming therapy resistance in EGFR-mutant lung cancer
1个月前
已完结
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
1个月前
已完结
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain
1个月前
已完结
Programming immune escape
3个月前
已完结
Three ways ChatGPT helps me in my academic writing
5个月前
已完结
Myeloid neoplasms post PARP inhibitors for ovarian cancer
7个月前
已完结
皖公网安备34019202002308
